Related Experiment Video

Updated: Jun 4, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose

Pongwut Danchaivijitr, Jean Yared, Aaron P Rapoport

    American Journal of Hematology
    |January 29, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Jun 4, 2026

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    Related Concept Videos

    Hypersensitivity Reactions: Cytolytic Reactions01:01

    Hypersensitivity Reactions: Cytolytic Reactions

    Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells.

    Cancers·2026

    Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy-A retrospective analysis.

    Neuro-oncology advances·2026

    Implementation of a Multidisciplinary Eye Clinic within a Cancer Center for Patients at Risk of Ocular Graft versus Host Disease.

    Ophthalmology science·2026

    Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.

    Blood·2026

    Predictors of Rehabilitation Utilization After CAR T-Cell Therapy.

    Transplantation and cellular therapy·2026

    Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.

    European journal of haematology·2026

    A Pooled CRISPR Screen Reveals Genes Critical for Erythroblast Enucleation.

    American journal of hematology·2026

    Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH).

    American journal of hematology·2026

    Proteomic Profiling of Nodal T-Follicular Helper Cell Lymphoma Reveals Distinct Biological Signatures and Improves Prognostic Stratification Beyond the IPI.

    American journal of hematology·2026

    Cerebral Small Vessel Disease in Immune-Mediated Thrombotic Thrombocytopenic Purpura Patients During the Acute Phase and Disease Remission.

    American journal of hematology·2026

    Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.

    American journal of hematology·2026

    Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.

    American journal of hematology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us